Hoth Therapeutics, Inc. (HOTH)
- Previous Close
1.1600 - Open
1.2100 - Bid 1.1300 x 100
- Ask 1.2600 x 100
- Day's Range
1.1950 - 1.2100 - 52 Week Range
0.9900 - 4.3000 - Volume
10,682 - Avg. Volume
447,258 - Market Cap (intraday)
5.842M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3000 - Earnings Date May 15, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.67
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
www.hoththerapeutics.comRecent News: HOTH
Performance Overview: HOTH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOTH
Valuation Measures
Market Cap
5.62M
Enterprise Value
-3.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.06%
Return on Equity (ttm)
-112.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.85M
Diluted EPS (ttm)
-2.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
9.29M
Total Debt/Equity (mrq)
0.63%
Levered Free Cash Flow (ttm)
-5.38M